Last close As at 05/08/2026
USD3.00
— 0.00 (0.00%)
Market capitalisation
—
Research: Consumer
The London Tunnels (TLT), which is redeveloping the historic Kingsway Exchange Tunnels beneath central London, is available for investment through the crowdfunding platform, Crowdcube, from 10 March 2026. Crowdcube is Europe’s most significant private market investment platform, enabling investors to gain access to companies earlier in their lifecycle, while potentially benefiting from future liquidity events before a possible public listing. TLT is looking to expand its investor community from its current base of over 400 shareholders by raising a maximum of £10m in this investment round on Crowdcube at £1.80 per share, a significant discount to the $3.00 per share at which they are being traded on JP Jenkins.
Through the crowdfunding round on Crowdcube, investors can invest as little as £100 and gain access to investor awards. The raise marks a significant step in opening the project to a wider community of investors. Until now, most investment opportunities with the project have typically required a minimum commitment of around £10k. The available investor awards scale with the level of investment as follows:
Additionally, the first 500 investors who register for early access will be invited to attend a tunnel tour, giving them the opportunity to see the project first-hand.
Since it was established in 2011, Crowdcube has grown to become Europe’s largest private
market platform, managing over
|
Historical financials |
||
|---|---|---|
| Year end | PBT (£m) | EPS (p) |
| 3/24 | (4.9) | (11.00) |
| 3/25 | 2.2 | 0.02 |
Australia
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
New Zealand
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
United Kingdom
This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
London │ New York │ Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom
Research: Healthcare
We update our investment view on Oryzon Genomics following the company’s FY25 results and refreshed profile. This includes an array of near-term milestones for iadademstat, lead asset for oncological- and non-oncological haematological diseases, such as clinical trial readouts for the ALICE-2 and RESTORE trials in 2026, in acute myeloid leukaemia (AML) and sickle cell disease (SCD), respectively. Separately, lead central nervous system (CNS) asset vafidemstat is Phase III-ready, as management is finalising the protocol for a pivotal-stage programme with European and US regulators in borderline personality disorder (BPD). As of end-2025, the company’s current gross cash position of €28.4m should provide operational headroom through H127. Reflecting these developments, our valuation for Oryzon stands at €938.2m, or €11.7/share.